SBIR/STTR Research Award
Endothelialized microfluidic assays for emerging therapies in sickle cell disease
Award amount
$1,694,949Program and phase
STTR · Phase IIAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BIOCHIP LABS, INC.
- Proposal award date
- 2022-04-05
- Contract end date
- 2024-03-31
- UEI
- K5TKCGKKA1T9
- Solicitation number
- PA20-265
- Topic code
- NHLBI
Research abstract
TBD
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Manufacturing and Analytical Validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for Commercial Viability
- STTR Phase II: Optimized manufacturing and machine learning based automation of Endothelium-on-a-chip microfluidic devices for drug screening applications.
- Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability (Administrative Supplement)
- Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability
- Endothelialized microfluidic assays for emerging therapies in sickle cell disease
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications
Research funding history
7 SBIR/STTR records share this UEI (2021–2025). Reported award amounts total $5,556,887. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation